FI4178548T3 - (s)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-yyli)-1-oksoisoindolin-4-yyl)oksi)metyyli)bentsyyli)piperatsin-1-yyli)-3-fluoribentsonitriiliä käsittäviä lääkekoostumuksia ja niiden käyttötapoja - Google Patents
(s)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-yyli)-1-oksoisoindolin-4-yyl)oksi)metyyli)bentsyyli)piperatsin-1-yyli)-3-fluoribentsonitriiliä käsittäviä lääkekoostumuksia ja niiden käyttötapoja Download PDFInfo
- Publication number
- FI4178548T3 FI4178548T3 FIEP21755119.1T FI21755119T FI4178548T3 FI 4178548 T3 FI4178548 T3 FI 4178548T3 FI 21755119 T FI21755119 T FI 21755119T FI 4178548 T3 FI4178548 T3 FI 4178548T3
- Authority
- FI
- Finland
- Prior art keywords
- amount
- mannitol
- composition according
- pharmaceutical composition
- cellulose
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 15
- 238000000034 method Methods 0.000 title claims 2
- YTINZZFBHWSAGL-NDEPHWFRSA-N cc-92480 Chemical compound O=C1NC(CC[C@@H]1N1C(C2=CC=CC(=C2C1)OCC1=CC=C(CN2CCN(CC2)C2=C(C=C(C#N)C=C2)F)C=C1)=O)=O YTINZZFBHWSAGL-NDEPHWFRSA-N 0.000 title 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 15
- 229930195725 Mannitol Natural products 0.000 claims 15
- 239000000594 mannitol Substances 0.000 claims 15
- 235000010355 mannitol Nutrition 0.000 claims 15
- 229920002472 Starch Polymers 0.000 claims 10
- 229920002678 cellulose Polymers 0.000 claims 10
- 239000001913 cellulose Substances 0.000 claims 10
- 235000010980 cellulose Nutrition 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 239000008107 starch Substances 0.000 claims 10
- 229940032147 starch Drugs 0.000 claims 10
- 235000019698 starch Nutrition 0.000 claims 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 9
- 229920003109 sodium starch glycolate Polymers 0.000 claims 9
- 229940079832 sodium starch glycolate Drugs 0.000 claims 9
- 239000008109 sodium starch glycolate Substances 0.000 claims 9
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 8
- 229940125904 compound 1 Drugs 0.000 claims 7
- 235000021355 Stearic acid Nutrition 0.000 claims 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 6
- 239000008117 stearic acid Substances 0.000 claims 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 229920000881 Modified starch Polymers 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063048998P | 2020-07-07 | 2020-07-07 | |
| PCT/US2021/040452 WO2022010854A1 (en) | 2020-07-07 | 2021-07-06 | Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)m ethyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4178548T3 true FI4178548T3 (fi) | 2024-08-14 |
Family
ID=77338767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21755119.1T FI4178548T3 (fi) | 2020-07-07 | 2021-07-06 | (s)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-yyli)-1-oksoisoindolin-4-yyl)oksi)metyyli)bentsyyli)piperatsin-1-yyli)-3-fluoribentsonitriiliä käsittäviä lääkekoostumuksia ja niiden käyttötapoja |
Country Status (22)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120004860A (zh) * | 2020-07-20 | 2025-05-16 | 江苏恒瑞医药股份有限公司 | 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
| PY0323128A (es) | 2002-09-10 | 2012-12-03 | Pharmacia Italia Spa | Formulacion sólida que comprende un compuesto de indolina, útil en el tratamiento de trastornos relacionados con proteina de quinasas |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| AU2016213879B2 (en) | 2009-05-19 | 2017-11-16 | Celgene Corporation | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
| CA2772275A1 (en) | 2009-09-18 | 2011-03-24 | Sanofi | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| SMT201900071T1 (it) | 2011-07-28 | 2019-02-28 | Rigel Pharmaceuticals Inc | Nuove formulazioni di (trimetossifenilammino)pirimidinile |
| TWI782395B (zh) | 2016-01-08 | 2022-11-01 | 美商西建公司 | 抗增生化合物,及其醫藥組合物及用途 |
| JP7258009B2 (ja) * | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| PL3796912T3 (pl) | 2018-05-23 | 2023-09-11 | Celgene Corporation | Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego |
| IL278854B2 (en) | 2018-05-23 | 2026-01-01 | Celgene Corp | Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile |
| CN108502097B (zh) | 2018-05-24 | 2023-06-30 | 江苏科技大学 | 一种可开闭月池挡板装置 |
| AU2020206692B2 (en) | 2019-01-09 | 2025-03-27 | Celgene Corporation | Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
-
2021
- 2021-07-06 ES ES21755119T patent/ES2988714T3/es active Active
- 2021-07-06 CN CN202180048076.XA patent/CN115867261B/zh active Active
- 2021-07-06 US US18/014,882 patent/US12472176B2/en active Active
- 2021-07-06 CA CA3184460A patent/CA3184460A1/en active Pending
- 2021-07-06 ES ES24179296T patent/ES3068915T3/es active Active
- 2021-07-06 EP EP21755119.1A patent/EP4178548B1/en active Active
- 2021-07-06 SM SM20240374T patent/SMT202400374T1/it unknown
- 2021-07-06 JP JP2023501163A patent/JP7868025B2/ja active Active
- 2021-07-06 RS RS20241101A patent/RS66027B1/sr unknown
- 2021-07-06 EP EP24179296.9A patent/EP4438043B1/en active Active
- 2021-07-06 KR KR1020237003869A patent/KR20230035598A/ko active Pending
- 2021-07-06 WO PCT/US2021/040452 patent/WO2022010854A1/en not_active Ceased
- 2021-07-06 PT PT217551191T patent/PT4178548T/pt unknown
- 2021-07-06 IL IL299657A patent/IL299657A/en unknown
- 2021-07-06 DK DK21755119.1T patent/DK4178548T3/da active
- 2021-07-06 HR HRP20241162TT patent/HRP20241162T1/hr unknown
- 2021-07-06 BR BR112023000248A patent/BR112023000248A2/pt unknown
- 2021-07-06 FI FIEP21755119.1T patent/FI4178548T3/fi active
- 2021-07-06 MX MX2023000292A patent/MX2023000292A/es unknown
- 2021-07-06 AU AU2021305052A patent/AU2021305052A1/en active Pending
- 2021-07-06 HU HUE21755119A patent/HUE068476T2/hu unknown
- 2021-07-06 PL PL21755119.1T patent/PL4178548T3/pl unknown
- 2021-07-06 LT LTEPPCT/US2021/040452T patent/LT4178548T/lt unknown
- 2021-07-06 SI SI202130179T patent/SI4178548T1/sl unknown
-
2025
- 2025-10-15 US US19/359,015 patent/US20260034122A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4438043A3 (en) | 2024-11-27 |
| EP4178548A1 (en) | 2023-05-17 |
| SI4178548T1 (sl) | 2024-10-30 |
| RS66027B1 (sr) | 2024-11-29 |
| DK4178548T3 (da) | 2024-08-19 |
| IL299657A (en) | 2023-03-01 |
| CN115867261A (zh) | 2023-03-28 |
| JP7868025B2 (ja) | 2026-06-01 |
| WO2022010854A1 (en) | 2022-01-13 |
| EP4438043C0 (en) | 2026-02-25 |
| JP2023533314A (ja) | 2023-08-02 |
| PL4178548T3 (pl) | 2024-11-12 |
| EP4178548B1 (en) | 2024-07-24 |
| HUE068476T2 (hu) | 2024-12-28 |
| LT4178548T (lt) | 2024-09-25 |
| MX2023000292A (es) | 2023-02-09 |
| PT4178548T (pt) | 2024-10-22 |
| SMT202400374T1 (it) | 2024-11-15 |
| ES2988714T3 (es) | 2024-11-21 |
| KR20230035598A (ko) | 2023-03-14 |
| US20260034122A1 (en) | 2026-02-05 |
| US20230270742A1 (en) | 2023-08-31 |
| AU2021305052A1 (en) | 2023-02-09 |
| EP4438043B1 (en) | 2026-02-25 |
| HRP20241162T1 (hr) | 2024-11-22 |
| CN115867261B (zh) | 2025-05-23 |
| CA3184460A1 (en) | 2022-01-13 |
| ES3068915T3 (en) | 2026-06-03 |
| EP4438043A2 (en) | 2024-10-02 |
| US12472176B2 (en) | 2025-11-18 |
| BR112023000248A2 (pt) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6875407B2 (ja) | Jakキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物 | |
| RU2450813C2 (ru) | Гипотензивная комбинация валсартана и блокатора кальциевых каналов | |
| JP4977462B2 (ja) | 3−[(2−{[4−(ヘキシルオキシカルボニルアミノ−イミノ−メチル)−フェニルアミノ]−メチル}−1−メチル−1h−ベンズイミダゾール−5−カルボニル)−ピリジン−2−イル−アミノ]−プロピオン酸エチルエステルまたはその塩を含む錠剤 | |
| RU2004134323A (ru) | Таблетка с высоким содержанием лекарственного препарата | |
| NZ520780A (en) | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure | |
| CA2541402A1 (en) | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7) en-2-yl)alkyl]phosphonic acid and derivatives | |
| SG173046A1 (en) | Solid pharmaceutical composition comprising amlodipine and losartan with improved stability | |
| RU2015151938A (ru) | Таблетируемый препарат (4'-трифторметилфенил)амида (z)-2-циано-3-гидрокси-бут-2-еноевой кислоты с улучшенной устойчивостью | |
| UA85359C2 (ru) | Таблетка, содержащая гранулированный материал с kmd-3213 | |
| JP2018154596A (ja) | アジルサルタン含有固形医薬組成物 | |
| JOP20240217A1 (ar) | مشتقات الكوينولين كمُعدِّلات للعضو x2 لمستقبل بروتين g مرتبط بـ mas ومنتجات ذات صلة | |
| RU2019135261A (ru) | Фармацевтическая композиция, содержащая ингибитор pde9 | |
| WO2014125124A1 (en) | Solid pharmaceutical dosage form of dolutegravir | |
| ES2881317T3 (es) | Composición farmacéutica que comprende sacubitrilo y valsartán | |
| WO2007061415A1 (en) | Pharmaceutical compositions of telmisartan | |
| MX2022009934A (es) | Composicion farmaceutica que comprende esomeprazol y bicarbonato de sodio con excelentes propiedades de liberacion. | |
| EA202193065A1 (ru) | Фармацевтическая композиция, содержащая акситиниб | |
| CA2577288A1 (en) | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile | |
| MX2025009791A (es) | Composicion farmaceutica de derivado de anillo heteroaromatico de benzo-nitrogeno y uso de la misma en medicina | |
| ES2719815T3 (es) | Composición farmacéutica oral de mesilato de imatinib y proceso para la preparación de la misma | |
| MXPA02000033A (es) | Polimorfos de un diclorhidrato cristalino de azobiciclo (2, 2, 2)oct-3-ilamina y sus composiciones farmaceuticas. | |
| ES2847904T3 (es) | Medicamento para la prevención o el tratamiento de la hipertensión | |
| WO2016189406A1 (en) | Pharmaceutical composition of teriflunomide | |
| AU2016385282A1 (en) | Pharmaceutical composition comprising nebivolol with improved dissolution rate | |
| US20070116759A1 (en) | Pharmaceutical compositions of telmisartan |